Category: Bispecific
Shots: F-star to receive $17.5M up front and is eligible to receive ~$1.35B as near-term fees & milestones along with royalties on net sales of the product Janssen to get an exclusive royalty-bearing license globally to research, develop & commercialize up to 5 novels bispecific Abs directed to Janssen therapeutic targets using F-star’s Fcab and […]
With that in mind, the 3rd Cell Engager Summit (June 30 – July 1) is the only industry-led meeting focused on developing multi-specific cell engaging therapies in solid tumor indications, and accelerating early discovery innovation into the clinic. With over 32 world-class speakers set to share their ground-breaking insights, this is a learning and networking experience you won’t want to […]
Shots: The company presented the new data of its T-cell engaging bispecific Abs, mosunetuzumab, glofitamab and cevostamab at ASH 2020, demonstrating encouraging activity across multiple types of blood cancer Roche divulges that its mosunetuzumab & glofitamab showed promising responses across multiple types of NHL, including R/R FL & DLBCL, reinforcing from the P-I/Ib GO29781 study […]